Kamel Mohammedi1,2,3, Stephen Harrap4, Giuseppe Mancia5, Michel Marre6,7,8, Neil Poulter9, John Chalmers10,11, Mark Woodward10,11,12,13. 1. Department of Endocrinology, Diabetes and Nutrition, Bordeaux University Hospital, Bordeaux, France. km.mmohammedi@gmail.com. 2. Faculty of Medicine, The University of Bordeaux, Bordeaux, France. km.mmohammedi@gmail.com. 3. INSERM Unit 1034, Bordeaux, France. km.mmohammedi@gmail.com. 4. The University of Melbourne and Royal Melbourne Hospital, Melbourne, VIC, Australia. 5. The University of Milan-Bicocca and Istituto Auxologico Italiano, Milan, Italy. 6. Université de Paris, UFR de Médecine, Paris, France. 7. Centre de Recherche Des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France. 8. CMC Ambroise Paré, Neuilly-sur-Seine, France. 9. The International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College, London, UK. 10. The George Institute for Global Health, Sydney, NSW, Australia. 11. The University of New South Wales, Sydney, NSW, Australia. 12. Faculty of Medicine, Imperial College London, London, UK. 13. Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA.
Abstract
BACKGROUND: Individuals with diabetes and lower-limb complications are at high risk for cardiovascular and all-cause mortality, but uncertainties remain in terms of cancer-related death in this population. We investigated this relationship in a large cohort of people with type 2 diabetes. METHODS: We used data from the Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation (ADVANCE) study. The primary outcome was adjudicated cancer death; secondary outcomes were overall and site-specific incident cancers, determined according to the International Classification of Diseases Code (ICD-10). We compared outcomes in individuals with (versus without) a baseline history of lower-limb complications (peripheral artery disease (PAD) or sensory peripheral neuropathy) using Cox regression models. RESULTS: Among 11,140 participants (women 42%, mean age 66 years), lower-limb complications were reported at baseline in 4293 (38%) individuals: 2439 (22%) with PAD and 2973 (27%) with peripheral neuropathy. Cancer death occurred in 316 (2.8%) participants during a median of 5.0 (25th-75th percentile, 4.7-5.1) years of follow-up corresponding to 53,550 person-years and an incidence rate of 5.9 (95% CI 5.3-6.6) per 1000 person-years. The risk of cancer death was higher in individuals with (versus without) lower-limb complication [hazard ratio 1.53 (95% CI, 1.21-1.94), p = 0.0004], PAD [1.32 (1.02-1.70), p = 0.03] or neuropathy (1.41 (1.11-1.79), p = 0.004], adjusting for potential confounders and study allocations. PAD, but not neuropathy, was associated with excess risk of incident cancers. CONCLUSIONS: PAD and peripheral neuropathy were independently associated with increased 5-year risk of cancer death in individuals with type 2 diabetes. PAD was also associated with increased risk of incident cancers. Our findings provide new evidence on the non-cardiovascular prognostic burden of lower-limb complications in people with type 2 diabetes.
BACKGROUND: Individuals with diabetes and lower-limb complications are at high risk for cardiovascular and all-cause mortality, but uncertainties remain in terms of cancer-related death in this population. We investigated this relationship in a large cohort of people with type 2 diabetes. METHODS: We used data from the Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation (ADVANCE) study. The primary outcome was adjudicated cancer death; secondary outcomes were overall and site-specific incident cancers, determined according to the International Classification of Diseases Code (ICD-10). We compared outcomes in individuals with (versus without) a baseline history of lower-limb complications (peripheral artery disease (PAD) or sensory peripheral neuropathy) using Cox regression models. RESULTS: Among 11,140 participants (women 42%, mean age 66 years), lower-limb complications were reported at baseline in 4293 (38%) individuals: 2439 (22%) with PAD and 2973 (27%) with peripheral neuropathy. Cancer death occurred in 316 (2.8%) participants during a median of 5.0 (25th-75th percentile, 4.7-5.1) years of follow-up corresponding to 53,550 person-years and an incidence rate of 5.9 (95% CI 5.3-6.6) per 1000 person-years. The risk of cancer death was higher in individuals with (versus without) lower-limb complication [hazard ratio 1.53 (95% CI, 1.21-1.94), p = 0.0004], PAD [1.32 (1.02-1.70), p = 0.03] or neuropathy (1.41 (1.11-1.79), p = 0.004], adjusting for potential confounders and study allocations. PAD, but not neuropathy, was associated with excess risk of incident cancers. CONCLUSIONS: PAD and peripheral neuropathy were independently associated with increased 5-year risk of cancer death in individuals with type 2 diabetes. PAD was also associated with increased risk of incident cancers. Our findings provide new evidence on the non-cardiovascular prognostic burden of lower-limb complications in people with type 2 diabetes.
Entities:
Keywords:
Cancer death; Cancers; Lower-limb complication; Peripheral arterial disease; Peripheral neuropathy; Type 2 diabetes
Authors: Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245
Authors: Donald M Lloyd-Jones; Yuling Hong; Darwin Labarthe; Dariush Mozaffarian; Lawrence J Appel; Linda Van Horn; Kurt Greenlund; Stephen Daniels; Graham Nichol; Gordon F Tomaselli; Donna K Arnett; Gregg C Fonarow; P Michael Ho; Michael S Lauer; Frederick A Masoudi; Rose Marie Robertson; Véronique Roger; Lee H Schwamm; Paul Sorlie; Clyde W Yancy; Wayne D Rosamond Journal: Circulation Date: 2010-01-20 Impact factor: 29.690
Authors: Eva L Feldman; Brian C Callaghan; Rodica Pop-Busui; Douglas W Zochodne; Douglas E Wright; David L Bennett; Vera Bril; James W Russell; Vijay Viswanathan Journal: Nat Rev Dis Primers Date: 2019-06-13 Impact factor: 52.329
Authors: Jessica L Harding; Linda J Andes; Edward W Gregg; Yiling J Cheng; Hannah K Weir; Kai M Bullard; Nilka Ríos Burrows; Giuseppina Imperatore Journal: Diabetologia Date: 2019-09-12 Impact factor: 10.122
Authors: Min Long; Montserrat Rojo de la Vega; Qing Wen; Manish Bharara; Tao Jiang; Rui Zhang; Shiwen Zhou; Pak K Wong; Georg T Wondrak; Hongting Zheng; Donna D Zhang Journal: Diabetes Date: 2015-12-30 Impact factor: 9.461
Authors: Claire M Buckley; Anne O'Farrell; Ronan J Canavan; Anthony D Lynch; Davida V De La Harpe; Colin P Bradley; Ivan J Perry Journal: PLoS One Date: 2012-07-31 Impact factor: 3.240